Loading clinical trials...

Cohort Study of Chronic Heart Failure | Clinical Trials | Clareo Health

RECRUITINGNA

Cohort Study of Chronic Heart Failure

NCT05960890•Jiangsu Taizhou People's Hospital

Summary

The goal of this observational study is to learn about the influencing factors of chronic heart failure prognosis in heart failure patients. The main question it aims to answer is that what are the influencing factors of clinical outcomes in chronic heart failure. Participants will be collected multiple omics data such as phenotype group, environmental exposure group, intestinal microbiome, genome, metabolome, and noninvasive biomarkers.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥18 years;
•2. Fulfill at least one of the following criteria：①History of chronic heart failure;②New-onset heart failure with LVEF \<50%；③New-onset heart failure with LVEF≧50%，E/e'≧15 and BNP\>400 pg/mL/NT-proBNP(\<50 years, \>450 pg/mL; 50\~75 years, \>900 pg/mL; \>75 years, \>1800 pg/mL)
•3. Etiology: dilated cardiomyopathy, hypertensive heart disease, ischaemic cardiomyopathy, Non-severe valvular heart disease；
•4. Primary post-discharge therapy: oral medication;
•5. Sign the informed consent form.

Exclusion Criteria

•1. Patients with renal failure (Ccr\<30ml/min) or patients on dialysis therapy;
•2. Various correctable secondary causes of cardiac insufficiency including hyperthyroid heart disease, anaemic heart disease, uncorrected congenital heart disease; severe valvular heart disease (including severe stenosis or closure of organic aortic and mitral valves);
•3. Patients with indications for pacemaker implantation but have not received a pacemaker implant;
•4. Patients with chronic obstructive pulmonary disease accompanied by type II respiratory failure.
•5. Patients who cannot understand and sign an informed consent form.
•6. Patients with mental illness, pregnant women, and other special populations.

Locations (1)

Taizhou People's Hospital affiliated to Nanjing Medical University

Taizhou, Jiangsu, China

Key Dates

Start Date

June 8, 2023

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2026

Last Updated

May 31, 2025

Enrollment

1,000

ESTIMATED participants

Conditions

Heart Failure

Interventions

Remote monitoring assisted by community physicians

BEHAVIORAL

Contacts

Yucheng Wu, Doctor

CONTACT

+8618360010750 2567181759@qq.com

Lichun Wang, Master

CONTACT

+8613775704547 18652711566@163.com

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

RECRUITINGNA

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 31, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cohort Study of Chronic Heart Failure

Inclusion Criteria

Exclusion Criteria

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Respiratory Virus Infections in Acute Heart Failure